DTILNasdaqBiological Products, (No Diagnostic Substances)

Precision Biosciences Inc (DTIL) earnings date, market-implied expected move, and options open interest by expiry

6.91

−0.06 · −0.88%

post 8.04 +16.30%

Closed15:59 ET

Open7.14Volume402,073Mkt cap$226.8MEPS-1.41

Day6.86 – 8.04100%52-wk3.53 – 9.6274%

DTIL

Precision Biosciences Inc

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

Next report

Jan 12

after close · in 69 days

est.Q4 FY26

Calendar

Next report

Last report

+0.29%

vs ±63.3% implied · ×0.00

shaded = implied · ▲▼ = realized

Nov 3 '26 · confirmedthin chain

Implied vs realized

Linked news

54dMXCT · supplierMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
62dTGTX · customerTG Therapeutics to Participate in the Cantor Global Healthcare Conference

News

Largest filed tie

13F top-10 QoQ

−2.33%

shares held · 10 largest managers

13F · Jun 30 '26128d lag

96 managers

Top fund weight

0.00%

DTIL weight · IWM

N-PORTJun 30 '26

3 funds

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Precision Biosciences (DTIL) is expected to report on Jan 12 after close (estimated date).

Implied vs realized

8 reports

—≥ implied

May 15 '25May 15 '25confirmed—▼−8.08%—

Aug 7 '25Aug 7 '25confirmed—▼−4.99%—

Q3 FY25Nov 3 '25confirmed—▼−9.80%—

Jan 13 '26Jan 13 '26confirmed—▲+0.49%—

Q1 FY26Mar 12 '26confirmed—▲+12.06%—

May 5 '26May 5 '26confirmed—▼−2.36%—

Q2 FY26Aug 6 '26confirmed±36.7%▼−0.67%×0.02

Q3 FY26Nov 3 '26confirmed±63.3%thin chain▲+0.29%×0.00

quarterimplied−65%0+65%realized×

Q3 FY26±63.3%▲+0.29%×0.00

Q2 FY26±36.7%▼−0.67%×0.02

May '26—▼−2.36%—

Q1 FY26—▲+12.06%—

Jan '26—▲+0.49%—

Q3 FY25—▼−9.80%—

2 older reports

Aug '25—▼−4.99%—

May '25—▼−8.08%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

OI · 2 expiries · Nov 4 close

0.02OI · 2 expiries · Nov 4 closeP/C open interest · Jan 15 · first expiry after the report

PUTS · chgexpiry · days · P/CCALLS · chgP/C

260%Nov 2016d0.10268+2%0.10

report · Jan 12 · after close · est.

180%Jan 1572d1,0960%

ExpiryPutsCallsP/C

Nov 2016d260%268+2%0.10

report · Jan 12 · after close · est.

Jan 1572d180%1,0960%0.02

Hatched = puts · solid = calls · bars scaled per expiry · chg = OI vs prior sessionSource: options EOD

Positioning

Linked exposure

No implied move.

Linked exposure

Revenue flow

as filedQ1 FY26

−170.15%as filednet margin · revenue −68.31% QoQ · +37272.41% YoY

Revenue$11M−68.31%

Gross profit$11M100.00%−68.31%

Operating income−$9M−83.73%−172.55%

Pre-tax income−$18M−193.71%

Net income−$18M−170.15%−191.60%

Cost of revenue$0—

Operating expenses$20M−10.04%

Other expense−$9M−230.59%

Source: SEC filings · standardized · QE Mar 31 '26 · bars = % of revenue

Revenue flow

Intraday

15m bars

Hatch = extended hours · ▯ up · ▮ downSource: market data · 16:00 ET

Intraday

Event sensitivity

FOMC ×1.11· ±3.7% vs ±3.3% · 24 releases

eventrelease day|move|up · n×base

FOMCrate decision±3.7%12 of 24×1.11

CPROFcorporate profits±3.0%6 of 12×0.89

PCEpersonal income & outlays±2.9%9 of 19×0.86

CPIconsumer prices±2.7%3 of 10×0.82

GDPgross domestic product±2.6%9 of 19×0.79

NFPjobs report±2.4%8 of 10×0.72

PPIproducer prices±2.0%6 of 10×0.60

Bar = avg |move| to ±4% · tick = ±3.3% avg day · ×base = |move| ÷ ±3.3% · min 6 releases

Earnings history

EPS -0.28 · consensus —

Quarter	Reported	EPS	Consensus
Q3 FY26	Nov 3 '26 · confirmed	-0.28	—
Q2 FY26	Aug 6 '26 · confirmed	-1.26	—
Q1 FY26	Mar 12 '26 · confirmed	-0.75	—
Q3 FY25	Nov 3 '25 · confirmed	-1.84	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod